AI Technology and Precision Medicine in Neurodegenerative Diseases

Dear Colleagues,

The field of artificial intelligence (AI) and precision medicine in neurodegenerative diseases is rapidly expanding, with the aim of enhancing the diagnosis, monitoring, and treatment of these conditions. Neurodegenerative dis-eases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and Huntington's disease, present a significant challenge to modern medicine due to their intricate causes, progressive nature, and restricted treatment options.

The use of artificial intelligence, including machine learning and deep learning, in the diagnosis of neurodegen-erative diseases opens new possibilities for identifying disease biomarkers at an early stage. The analysis of large datasets from brain imaging (MRI and PET), genetic data, and other biological parameters using AI algorithms can significantly increase the precision and speed of diagnosis of these diseases. This makes it possible to diagnose and implement interventions early, which may slow disease progression.

Precision medicine for neurodegenerative diseases uses AI technology to develop personalized treatment strate-gies. By analyzing complex patient datasets, AI algorithms can predict treatment responses and identify subpop-ulations of patients most likely to benefit from specific interventions. This allows for a more targeted therapeutic approach, increasing the chance of therapeutic success and minimizing the risk of side effects.

Artificial intelligence and precision medicine have significant potential in the fight against neurodegenerative diseases, offering new tools for better diagnosis, monitoring, and personalization of therapies. Despite these challenges, continued research and development of AI technologies can significantly contribute to improving the quality of life of patients and the efficiency of healthcare systems.

Therefore, taking into consideration the significance of AI and precision medicine in neurodegenerative diseases, I would like to strongly encourage you to prepare a manuscript situated within this developing field of neurology.

Dr. Stanisław Szlufik
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• AI
• machine learning
• precision medicine
• Parkinson’s disease
• Alzheimer’s disease
• neurodegenerative disorders
• wearable sensors
• new technologies